Amivantamab (EGFR×MET), approved for non-small-cell lung cancer (NSCLC) with EGFR exon 20 insertions, combines dual receptor blockade with Fc-mediated cytotoxicity (39, 67). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.